featured
Second Intravenous Immunoglobulin Dose in Patients With Guillain-Barré Syndrome With Poor Prognosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Second Intravenous Immunoglobulin Dose in Patients With Guillain-Barré Syndrome With Poor Prognosis (SID-GBS): A Double-Blind, Randomised, Placebo-Controlled Trial
Lancet Neurol 2021 Apr 01;20(4)275-283, C Walgaard, BC Jacobs, HF Lingsma, EW Steyerberg, B van den Berg, AY Doets, SE Leonhard, C Verboon, R Huizinga, J Drenthen, S Arends, IK Budde, RP Kleyweg, K Kuitwaard, MFG van der Meulen, JPA Samijn, FH Vermeij, JBM Kuks, GW van Dijk, PW Wirtz, F Eftimov, AJ van der Kooi, MPJ Garssen, CJ Gijsbers, MC de Rijk, LH Visser, RJ Blom, WHJP Linssen, EL van der Kooi, JJGM Verschuuren, R van Koningsveld, RJG Dieks, HJ Gilhuis, K Jellema, TC van der Ree, HME Bienfait, CG Faber, H Lovenich, BGM van Engelen, RJ Groen, ISJ Merkies, BW van Oosten, WL van der Pol, WDM van der Meulen, UA Badrising, M Stevens, AJ Breukelman, CP Zwetsloot, MM van der Graaff, M Wohlgemuth, RAC Hughes, DR Cornblath, PA van DoornFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.